Hiroaki Soyama
Overview
Explore the profile of Hiroaki Soyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soyama H, Okuguchi S, Yoshida T, Taniguchi F
Cureus
. 2023 Feb;
14(12):e33057.
PMID: 36721610
Unilateral partial absence of the fallopian tube is rare, and its clinical importance in fertility is unclear. A 35-year-old nulligravid female patient with infertility was suspected to have a left...
2.
Ivell R, Vinggaard A, Soyama H, Anand-Ivell R
Andrologia
. 2022 Sep;
54(11):e14566.
PMID: 36054713
Insulin-like peptide 3 (INSL3) is a peptide biomarker secreted specifically by the mature Leydig cells of the testes. It is constitutive, has low within-individual variance, and effectively measures the functional...
3.
Anand-Ivell R, Tremellen K, Soyama H, Enki D, Ivell R
Andrology
. 2021 Mar;
9(4):1126-1136.
PMID: 33715296
Background: Insulin-like peptide 3 (INSL3) is a constitutive, secreted peptide produced in the male uniquely by the Leydig cells of the testes. It is a biomarker for Leydig cell functional...
4.
Soyama H, Miyamoto M, Ishibashi H, Iwahashi H, Matsuura H, Kakimoto S, et al.
J Obstet Gynaecol Res
. 2020 Sep;
46(12):2526-2533.
PMID: 32924271
Aim: To investigate the differences in epithelial-mesenchymal transition (EMT)- and matrix metalloproteinases (MMP)-related factors among placenta previa with and without placenta accreta spectrum (PAS) (n = 69), and normal placenta...
5.
Hada T, Miyamoto M, Ishibashi H, Kawauchi H, Soyama H, Matsuura H, et al.
In Vivo
. 2020 May;
34(3):1341-1346.
PMID: 32354928
Aim: To examine the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and compare them with those of mucinous borderline/atypical proliferative mucinous tumors (MB/APMTs). Patients And Methods: Patients with SMBT...
6.
Soyama H, Miyamoto M, Matsuura H, Iwahashi H, Kakimoto S, Ishibashi H, et al.
Cancer Chemother Pharmacol
. 2020 Apr;
85(5):941-947.
PMID: 32279102
Purpose: The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and...
7.
Nakatsuka M, Miyamoto M, Soyama H, Takano M, Sasa H, Furuya K
J Obstet Gynaecol
. 2019 Jun;
39(7):1022-1024.
PMID: 31215312
No abstract available.
8.
Soyama H, Miyamoto M, Takano M, Furuya K
Taiwan J Obstet Gynecol
. 2019 May;
58(3):440.
PMID: 31122540
No abstract available.
9.
Takasaki K, Miyamoto M, Takano M, Soyama H, Aoyama T, Matsuura H, et al.
Int J Clin Oncol
. 2019 May;
24(10):1273-1283.
PMID: 31073813
Background: This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma. Methods: Patients with ovarian carcinoma treated at our hospital...
10.
Miyamoto M, Takano M, Tsuda H, Ishibashi H, Soyama H, Matsuura H, et al.
Anticancer Res
. 2019 Apr;
39(4):2085-2089.
PMID: 30952753
Background/aim: This study aimed to evaluate the clinical significance of lymphocyte infiltration (LI) for patients with endometrial serous carcinoma and those with endometrioid carcinoma including serous component. Patients And Methods:...